$184.64 -5.77 (-3.03%)

Quest Diagnostics Inc. (DGX)

Quest Diagnostics Inc. (DGX) is a leading provider of diagnostic testing, information, and services that help clinicians, health plans, and laboratories improve patient care. Founded in 1967 and headquartered in Irving, Texas, the company offers a broad range of laboratory testing services, including clinical chemistry, molecular diagnostics, and pathology, supporting healthcare providers with insights to inform treatment decisions.

Dividend Yield 1.71%
Payout Frequency Quarterly

Dividend History

Pay DateAmountEx-DateRecord Date
October 20, 2025$0.802025-10-032025-10-03
July 21, 2025$0.802025-07-072025-07-07
April 21, 2025$0.802025-04-072025-04-07
January 29, 2025$0.752025-01-142025-01-14
October 21, 2024$0.752024-10-042024-10-04

Dividends Summary

Company News

Fertility Test Market Report 2025-2033, with Profiles of Quest Diagnostics, Mayo Clinic Laboratories, Ovation Fertility, Illume Fertility, Proov, BioMerieux, Labcorp, CCRM Fertility, and Maven Clinic
GlobeNewswire Inc. • Researchandmarkets.Com • October 21, 2025

Global fertility test market projected to grow from $7.92 billion in 2025 to $14.74 billion in 2033, driven by lifestyle changes, delayed pregnancies, and increasing infertility rates worldwide.

Quest Diagnostics Declares Quarterly Cash Dividend
Benzinga • Prnewswire • August 13, 2025

Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on October 20, 2025, to shareholders of record as of October 3, 2025.

Why Quest Diagnostics Stock Was Blasting Higher Today
The Motley Fool • Eric Volkman • January 30, 2025

Quest Diagnostics, a leading healthcare testing specialist, reported strong Q4 2024 results, beating analyst estimates on both revenue and earnings. The company's revenue grew 15% year-over-year, and it provided positive guidance for 2025, indicating continued growth in the aging American population's healthcare needs.

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
Zacks Investment Research • N/A • August 1, 2024

Labcorp reported strong Q2 2024 results, with adjusted EPS up 15.2% and revenues up 6.2% year-over-year. The company saw organic growth in its Diagnostics Laboratories segment, but cut its full-year adjusted EPS guidance due to the dilution impact of the Invitae acquisition.

Baird highlights strategic partnerships in Quest Diagnostics shares target increase By Investing.com - Investing.com
Investing.com • Emilio Ghigini • July 5, 2024

Baird raised the price target for Quest Diagnostics shares to $153 from $145, citing the company's strategic partnerships, including a new deal with LifeLabs, as well as the integration of the Allina model into their valuation.

Related Companies